Abstrak
Therapeutic effect of Acalypha indica extract in frogs
In 2006, the morbidity rate of stroke incidence in patients with hypertension due to cerebral thrombosis was about 83%, while 70% of these cases were caused by cerebral hemorrhage. One third of these patients recovered successfully from remaining symptoms, but two thirds of them had still persistent neurological disorders characterized by musculoskeletal paralysis such as hemiplegia or hemiparese. 1 To treat such persistent symptoms, various conventional chemical drugs have been used despite their high cost, uncertain or still questionable effi cacy between their benefi t and risk, and/or aggravating side effects such as sleeping disorder, anxiety and depression, e.g., piracetam. 2 Hypertensive patients often turned their choice to alternative or complementary traditional herbal medicine, such as celery (Apium graveolens Linn.) 3 , garlic (Allium sativum Linn.) 4 , and mahkota dewa (Phaleria marcocarpa Scheff.) 5 . These herbs are consumed separately or in combination to treat hypertension but not as remedies for paralysis or hemi-/paraplegia that may have occurred as a result of the hypertensioncaused stroke and its remaining post-stroke symptoms.
In some Indonesian communities, root extract with boiling water of akar kucing (Acalypha indica Linn.) has been used traditionally to reduce or even heal such remaining symptoms. However, no data has been established as a reference on the benefi cial magnitude of Acalypha indica in the treatment of neurological disorders in vivo.
Previously, it was demonstrated that the aqueous root extract from Acalypha indica Linn. has neuro-protective and neuro-therapeutic effects on gastrocnemius muscles of frogs in ex vivo studies 6 . Therefore, a similiar experimental in vivo study in frogs was performed. The frogs were considered as an experimental animal model based on the data of these previous studies which used isolated frog nerves and muscles ex vivo in order to examine membrane transport and activity of neurotransmitters. [7] [8] In a preliminary study 6 , pancuromium bromide was used as a model substance to induce neural paralysis and its dosage was adjusted to 2 mg/ml (0.2%) at 1:20 dilution for subcutaneous (s.c.) administration, equivalent to 0.1 mg per frog.
The dosage of root extract was determined based on the ex vivo studies to 6, 9, 12, 15 mg or 200, 300, 400, 500 mg/kgBW, respectively, at an average body weight per frog of 30 grams.
From the ex vivo studies, it was expected that the results of the present study would also demonstrate protective and/or therapeutic effects of the root extract from Acalypha indica L. on the frogs' nerve system in vivo. Therefore, this animal model was chosen as a novel access in this preliminary study.
The general objective of this study was to prove that the root extract of Acalypha indica Linn. (akar kucing) has neural protective and therapeutic effects in vivo.
The specifi c objective was to prove that the root extract of Acalypha indica Linn. in a dose range of 6, 9, 12 and 15 mg or 200, 300, 400, 500 mg/kgBW has protecting and therapeutic effects on the nerves innervating the frog musculoskeletal system in vivo paralyzed by subcutaneous injection of pancuronium bromide. The extract dosage was adjusted to 200, 300, 400, 500 mg/kgBW or 6, 9, 12, 15 mg for each frog, respectively, and piracetam as the positive control at 30 mg/ frog or 1,000 mg/kgBW. Pancuronium bromide 0.1 mg per frog was administered by subcutaneous (s.c.) injection. This dosage had been optimised experimentally in a preliminary study 6 .
METHODS

Group I: Neuroprotective effect
This part of the study was conducted in six subgroups: negative control (water); positive control (piracetam); the aqueous root extract of Acalypha indica Linn. with doses of 6 mg; 9 mg; 12 mg; 15 mg per frog, were given orally an hour before s.c. administration of pancuronium bromide 0.1 mg. The onset of action and duration of paralysis (in minutes) and the time (scored) needed to recover to normal condition were the parameters measured.
Group II: Neurotherapeutic effect
This part of the study was also conducted in six subgroups: negative control (water); positive control (piracetam); the aqueous root extract of Acalypha indica Linn. with doses of 6 mg; 9 mg; 12 mg; 15 mg per frog, were given orally, 10 minutes after subcutaneous injection of pancuronium bromide. The duration of paralysis (in minutes) and scored recovery time to normal condition were the parameters measured.
Statistics
Each group in this study consisted of 5 frogs, thus SD was evaluated from n=5. The onset of action (only for protection), duration of paralysis and recovery time (in minutes), both for protective or therapeutic effects were analyzed statistically by using one-way Anova with limit of signifi cance at p=0.05.
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RESULTS
Group I: Neuroprotective effects (Figs.1-3).
Neuroprotective effects in frogs paralyzed with 0.1mg pancuronium bromide in vivo showed a maximum at dose 12mg or 400mg/kgBW, but the entire dose range from 6mg to 15mg (or 200-500mg/kgBW) had equivalent or even stronger effects than the positive control group with piracetam 30mg. Figure 1 shows that frogs which obtained the extract one hour before injection of pancuronium bromide, experienced paralysis within 14-25 minutes, whereas in the negative control group onset of paralysis was after 9±1.4 minutes and in the positive control group of piracetam after 11±1.6 minutes. In other words, onset of paralysis was slower over the whole range dose from 6mg to 15mg of extract as compared to both, negative and positive controls. The peak of effi cacy in this experiment is at 25±2.2 minutes with 12mg of extract (Fig.1) . The protective effect of 12mg and 15mg (22±2.0 min.) of extract is signifi cantly different from both negative and positive controls (p<0.05).
Onset of paralysis
Duration of paralysis
During an observation time of 2 hours, 12mg of extract showed a maximum protective effect on the duration of paralysis (59±2.0 min) induced by pancuronium bromide followed by 9mg with a duration time of 77±2.5 minutes. This is signifi cantly (p<0.05) shorter than negative controls (112±5.0 min) but only 12mg of extract shortens duration of paralysis also signifi cantly towards positive control of piracetam (81±2.8 min, p<0.05). The other treatment groups with 6mg and 15mg of the extract showed 83±3.4 and 83±3.2 min. duration time of paralysis comparable to piracetam. In other words, duration of paralysis was shorter over the whole range of dosage from 6mg to 15mg of extract as compared to negative control, with 12mg being also signifi cantly more effective than piracetam 30mg (Fig.2) . 
Therapeutic effect of Acalypha indica extract in frogs
Complete recovery
Complete recovery took about 2 hours in the control group which had only been given water through the nasogastric tube, i.e., these frogs did not wake up before 2 hours of observation. Based on this data, the groups were catagorised as follows: unawake after 2 hours (>120 minutes) = score 5; awake between 90-120 min = score 4; 60-90 min = score 3; 30-60 min = score 2; and less than 30 minutes = score 1.
The negative control group thus scored 4.25 and the piracetam group as positive control scored 3.8. Administration of 12 and 15mg of extract resulted in recovery scores of 2.4 and 2.5, respectively (Fig. 3) , which values are signifi cantly different from both negative control and piracetam groups (p <0.05). The other two treatment groups with 6mg and 9mg of extract and a score of 3.0 were also more effective than piracetam, although the difference is not signifi cant. However, all treatment groups differ signifi cantly from the negative control group. Also in this experiment, the administration of 12mg of extract shows a maximum effect (Fig. 3) . Statistical evaluation was performed with the original values in minutes before scoring.
Group II: Neurotherapeutic effect (Figs.4 and 5).
Duration of paralysis
This experiment resembles that one shown in Fig. 2 , the difference is that the extract was now administered 10 min after the injection of pancuronium bromide. The results are depicted in Figure 4 . (Fig. 4) .
Complete recovery
After 2 hours of observation, all values in the dose range of 6-15mg of extract per frog demonstrated signifi cantly shorter complete recovery times from paralysis between 27±1.4 min for the group with 12mg and 44±1.6 min for the doses of 9mg and 15mg (p=0.000-0.003) vs negative controls (115±5.6 min) and positive controls piracetam (58 ±2.0 min; p=0.000-0.316). These results were scored in the same way as explained in the context of Fig.3 and are depicted in 
Summary
A signifi cant neuroprotective effect of Acalypha indica Linn. extract on frogs paralyzed with pancuronium bromide in vivo has been shown at a dosage of 12mg per frog or 400 mg/kgBW, while the whole dose range of extract (6-15mg or 200-500 mg/kgBW) exerted a signifi cant therapeutic effect compared to the negative control group with a maximum effect at 9-12mg or 300-400 mg/kgBW.
DISCUSSION
Acalypha indica Linn. (akar kucing)
10,11
Nahrstedt et al. isolated acalyphin from Acalypha indica Linn. and published its structure in 1982 10 and it was considered the active compound 11 although a variety of other compounds have been isolated from Acalypha indica 12, 13 . Various extracts from this plant had been shown to have diurectic 14 , antimicrobial 15 , scavenging activity 16 , and antifertility 17 effects, however not all extracts were decocts from the plant's roots as proven for the antiurisemic activity in rats 18 . In our study, a standardised aqueous extract from the roots was applied.
Frogs as animal models
Frogs have been used classically for demonstration of neuro-musculoskeletal effects in the laboratories of physiology and pharmacology and numerous studies generally using this ex vivo neuro-musculoskeletal model support its validity [7] [8] . Therefore, also our working group used this ex vivo model in a preliminary study. 6 The present study demonstrating protective and therapeutic effects of Acalypha indica Linn. (akar kucing) extract in living frogs provides evidence that frogs can be used as an in vivo animal model for innervation, both in peripheral and central nervous systems.
Piracetam
From innumerous publications on the effects of piracetam, only few which may be considered in the context of "positive control" in the present study are selected. Clinically doses of piracetam up to grams are applied in therapy and the offi cial safety data sheet denotes LD 50(mouse) of 2,000g/kgBW. There for, in our study the dosage of 1,000mg/kgBW was chosen, equivalent to 30mg per frog. Piracetam is thought have impact on acetylcholine via muscarinic cholinergic receptors and on NMDA glutamate receptors and may modulate ion channels and thus membrane permeability [19] [20] [21] [22] . Furthermore, in animal models there appears to be an effect on cerebral/neural mitochondrial energy metabolism, electron transport and ATP synthesis [23] [24] .
Dosage fi nding of the extract
The effective dose in frogs in vivo, 20 times the dose of ex vivo study (200-500 mg/kg BW or 6-15 mg/frog, at an average body weight of 30 g), was lower than ex vivo study using neuromuscular junction's model .i.e. 10; 15; 20; 25 mg/sample, because of their body weight, both the protective and therapeutic effect 6 .
Effects
In the neuroprotective set of experiments, the extract is superior over piracetam 30mg which is even statistically signifi cant at higher extract dosages of 12-15mg. From these experiments different from the plant extract, piracetam does not exert protective effi cacy.
In the therapeutic set of experiments, piracetam exerts a siginifi cant effect vs controls, as does the plant extract at all dosages from 6-15mg. However, at a dose of 9mg, the extract is signifi cantly more effective than 30mg of piracetam.
In both sets of experiments, the plant extract exerts a bellshaped pharmacodynamic action with peaks at 12mg for the protective effect and at 9mg for therapy. These dosages are also signifi cantly superior over our reference compound piracetam at the applied dose of 30mg. . Furthermore, as often in herbal medicines, it is the specifi c composition of extracts that causes pharmacological effects.
The effective dose of this extract as neurotherapeutic agent was lower (300 mg/kgBW) than its neuroprotective dosage (400-500 mg/kgBW). Since the effect was better than that of piracetam the extract of Acalypha indica Linn. will be promising to be choosen as complementary or alternative herbal medicine to treat neurologic disorders, especially in central nervous system although the mechanism of action cannot yet fully be explained.
Although frogs can be used at least as a fi rst or preliminary animal model as demonstrated in this study, further studies have to be conducted with another animal model using mice or rats. Furthermore, the mechanism of action of the extract as a neuroprotecting and neurotherapeutic agent has to be demonstrated yet in central and peripheral nervous systems. To this end a model not using pancuronium bromide should be used in order to exclude that the extract might just counteract this compound in terms of a competitive antagonist. The aim of future studies should also be done to improve the extract as a standardized herbal medicine for the treatment of central or peripheral neural paralysis, either in the central nervous system or in neuromuscular junction.
In conclusion, the results of this study indicate that the extract of Acalypha indica Linn. has neuro-protective and neurotherapeutic effects in frogs in vivo. From our interpretation it is suggested that the extract acts as a competitive inhibitor to pancuronium bromide in neuromuscular junction, both in neuroprotective and neurotherapeutic sets of experiments. However, further studies should be performed in other animal models to prove its mechanism of action in preclinical pharmacokinetic and pharmacodynamic studies.
